Servier Canada
Asparlas®
ASPARLAS logo; ASPARLAS calaspargase pegol for injection

Dosing and administration1

The recommended dose of ASPARLAS® is 2500 IU/m2 administered as IV infusion no more than every 21 days.1

The recommended dose of ASPARLAS® is 2500 IU/m2 administered as IV infusion no more than every 21 days.

Adapted from the ASPARLAS® Product Monograph. Please see the ASPARLAS® Product Monograph for complete dosing information.

  • ASPARLAS® is a preservative-free, clear and colorless solution. If particulate matter, cloudiness, or discoloration are present, discard the vial. Do not administer if ASPARLAS® has been shaken or vigorously agitated, frozen, or stored at room temperature for > 48 hours.
  • Dilute ASPARLAS® solution in 100 ml of 0.9% sodium chloride or 5% dextrose solution prior to administering as an IV infusion over a period of 1-2 hours, through an infusion that is already running.
  • After dilution, administer immediately into a running infusion of either 0.9% sodium chloride or 5% dextrose.

Administer over a period of 1-2 hours.

Do not infuse other drugs through the same IV line during administration.

Monitor patients at least weekly during cycles of treatment that include ASPARLAS® and through 6 weeks after the last dose of ASPARLAS®. (e.g., bilirubin, transaminases, glucose and clinical examinations until recovery from the cycle of therapy).

If an AE should occur, modify treatment according to the Product Monograph.

  • ASPARLAS® is used as part of combination chemotherapy protocols with other antineoplastic agents.
  • ASPARLAS® is not a bioequivalent alternative to pegaspargase.
  • In a multi-agent chemotherapeutic regimen, ASPARLAS® at the same dose and frequency as pegaspargase may increase toxicities due to the longer half-life of calaspargase pegol.

Please consult the Product Monograph for the complete information on dosing and administration.

Learn more about Servier Canada’s treatment options in ALL

Learn more

Consult the ASPARLAS® Product Monograph

Learn more

aBFM: augmented Berlin-Frankfurt-Münster; AE: adverse event; ALL: acute lymphoblastic leukemia; ALP: alkaline phosphatase; ALT: alanine aminotransferase; aPTT: activated partial thromboplastin time; AST: aspartate aminotransferase; BFM: Berlin-Frankfurt-Munster; BSA: body surface area; CSF: cerebrospinal fluid; CTCAE: Common Terminology Criteria for Adverse Events; DFCI: Dana-Farber Cancer Institute; IM: intramuscular; IV: intravenous; NCCN: National Comprehensive Cancer Network®; NPAA: nadir plasma arparaginase activity; NSAA: nadir serum asparaginase activity; NSAID: non-steroidal anti-inflammatory drug; PD: pharmacodynamics; PK: pharmacokinetics; TDM: therapeutic drug monitoring.

* Comparative clinical significance has not been established.
† Fictitious cases. May not be representative of all patients.
‡ Clinical significance has not been established.

References:

  1. ASPARLAS® Product Monograph. Servier Canada.
  2. Data on file. Servier Canada.
  3. ONCASPAR® Product Monograph. Servier Canada.
  4. RYLAZE™ Product Monograph. Jazz Pharmaceuticals Canada Inc.
  5. Government of Canada. Summary Basis of Decision for Asparlas. Available at https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1718207489396.
  6. Government of Canada. ONCASPAR_CPID Redacted.
  7. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.
  8. Mank V, Azhar W, Brown K. Leukocytosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; April 21, 2024.
  9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Acute Lymphoblastic Leukemia, version 4.2023 – February 05, 2024.
  10. Vrooman LM et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: Results of DFCI 11-001. J Clin Oncol. 2021;39(31):3496–3505.
  11. National Institutes of Health. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE): Version 4.0. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5×11.pdf. Accessed December 11, 2024.
Back to top

Stay Connected with Servier Canada

Stay up to date on disease information, treatment options, our products, and patient support programs.

Sign Up